Takeda Pharmaceutical Company has announced breakthrough results from Phase 3 trials of zasocitinib (TAK-279), an innovative oral treatment for moderate-to-severe plaque psoriasis that offers patients a promising new option for…
Menopause-related insomnia affects approximately one in four women during the menopausal transition, yet it remains significantly underdiagnosed and undertreated. A new analysis published in Maturitas journal and reported by The…
Axsome Therapeutics has reached a significant regulatory milestone with the US Food and Drug Administration's acceptance of a supplemental New Drug Application (NDA) for AXS-05 as a treatment for agitation…
Soleno Therapeutics has achieved a significant milestone in the treatment of a rare genetic disorder, announcing the publication of pivotal clinical study results for VYKAT™ XR in the prestigious Journal…
ImmunityBio's latest clinical findings reveal a significant development in the ongoing battle against non-muscle-invasive bladder cancer, with three-year follow-up data suggesting that combining Anktiva with standard immunotherapy could fundamentally alter…
FibroBiologics Inc, a clinical-stage biotechnology company, has announced a significant breakthrough in regenerative medicine by submitting a Phase 1/2 Investigational New Drug (IND) application to the US Food and Drug…
When pharmaceutical companies develop medications for serious diseases like prostate cancer, few anticipate how those treatments might transform care for entirely different patient populations. Yet, according to FiercePharma.com, Foresee Pharmaceuticals…
Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating continued weight loss and…
Coya Therapeutics has achieved an important regulatory milestone with U.S. FDA acceptance of an Investigational New Drug (IND) application for COYA 302, marking the advancement of a promising new treatment…
A new oral medication has demonstrated remarkable effectiveness in treating hereditary angioedema (HAE) attacks, offering patients significantly faster symptom relief compared to existing options. According to Healio.com, the RAPIDe-3 study…
Researchers at Oregon Health & Science University have made a significant breakthrough in the fight against acute myeloid leukaemia (AML), discovering that combining a standard AML treatment with a breast…
Otsuka has claimed a significant victory in the increasingly competitive immunoglobulin A nephropathy (IgAN) field with FDA accelerated approval of Voyxact, the first-in-class anti-APRIL biologic therapy designed to treat this…
A groundbreaking study from Massachusetts General Hospital reveals that artificial intelligence is catching breast cancers that skilled radiologists initially overlook. As reported by Business Wire, Hologic's Genius AI Detection solution…
Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial on December 15, 2025 and reported by Drugs.com, marking a significant advancement in HIV treatment options. The trial…
A groundbreaking study published in Neurology and reported by Drugs.com reveals that adults with type 2 diabetes who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of medications increasingly…
When life-threatening pustules suddenly erupt across the body accompanied by systemic inflammation, generalized pustular psoriasis (GPP) patients face a medical crisis with few treatment options. As reported by PharmaBiz.com, Vanda…
Eccogene, a clinical-stage biopharmaceutical company, has announced enrollment of the first patient in MOSAIC, a Phase 2a clinical trial investigating two novel oral small molecules for treating metabolic dysfunction-associated steatohepatitis…
GSK announced a significant milestone in respiratory medicine as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Nucala (mepolizumab) for treating uncontrolled…
Eli Lilly presented compelling clinical evidence positioning its BTK inhibitor Jaypirca as a potentially superior treatment option compared to the established blood cancer therapy Imbruvica, marking a significant competitive shift…
The biotech sector witnessed significant momentum as four clinical-stage companies announced compelling data across muscular dystrophy, immunology, and obesity treatment areas, triggering substantial stock market gains and investor enthusiasm for…
Genentech announced landmark clinical trial results demonstrating that giredestrant, an investigational selective estrogen receptor degrader (SERD), significantly outperforms standard endocrine therapy in treating early-stage ER-positive breast cancer. As reported by…
Parabilis Medicines has achieved a significant milestone in cancer drug development, receiving FDA Fast Track designation for FOG-001, a groundbreaking first-in-class therapy targeting desmoid tumors. As reported by Drugs.com, this…
In a significant development for neurodegenerative disease treatment, BioPharma Dive reports that AC Immune has unveiled compelling evidence that its novel immunological strategy may fundamentally alter how the medical community…
An experimental cancer vaccine from the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy has delivered encouraging results in a phase I trial for fibrolamellar carcinoma…
Researchers at the University of Southampton have uncovered a hidden culprit in blood cancer, a unique sugar molecule that disguises aggressive lymphoma cells and renders them resistant to conventional treatments.…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
